{"address1": "Carl Jacobsens Vej 30", "address2": "Valby", "city": "Copenhagen", "zip": "2500", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 2682, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 63, "title": "Co-Founder, President & CEO", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 2958020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Pagano CPA", "age": 46, "title": "Executive VP & CFO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 1087508, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rayne  Waller", "age": 56, "title": "Executive VP & Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 736605, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 63, "title": "Executive VP & Chief Legal Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 710505, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Cozic", "age": 45, "title": "Executive VP & Chief People Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 797506, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martine J. van Vugt Ph.D.", "age": 53, "title": "Executive VP & Chief Strategy Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 754005, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 47, "title": "Senior Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 203001, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 66, "title": "Executive VP & Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 1232509, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi M.D., Ph.D.", "age": 51, "title": "Executive VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 1145508, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 50, "title": "Senior Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 232002, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.genmab.com/index.cfm", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 19.58, "open": 19.09, "dayLow": 18.622, "dayHigh": 19.1, "regularMarketPreviousClose": 19.58, "regularMarketOpen": 19.09, "regularMarketDayLow": 18.622, "regularMarketDayHigh": 19.1, "payoutRatio": 0.0, "beta": 0.903, "trailingPE": 10.602273, "forwardPE": 13.328571, "volume": 1793591, "regularMarketVolume": 1793591, "averageVolume": 1512646, "averageVolume10days": 1228820, "averageDailyVolume10Day": 1228820, "bid": 18.61, "ask": 18.72, "bidSize": 11, "askSize": 11, "marketCap": 12011012096, "fiftyTwoWeekLow": 18.622, "fiftyTwoWeekHigh": 30.5, "priceToSalesTrailing12Months": 0.55797696, "fiftyDayAverage": 20.8157, "twoHundredDayAverage": 23.392525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -18886340608, "profitMargins": 0.3644, "floatShares": 62847591, "sharesOutstanding": 634257024, "sharesShort": 3064293, "sharesShortPriorMonth": 1646872, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 7e-05, "heldPercentInstitutions": 0.09307, "shortRatio": 1.98, "shortPercentOfFloat": 0.0049, "impliedSharesOutstanding": 643676992, "bookValue": 577.54, "priceToBook": 0.03230945, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 4.469, "netIncomeToCommon": 7843999744, "trailingEps": 1.76, "forwardEps": 1.4, "lastSplitFactor": "5:1", "lastSplitDate": 1525132800, "enterpriseToRevenue": -0.877, "enterpriseToEbitda": -2.556, "52WeekChange": -0.36313993, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 18.66, "targetHighPrice": 50.0, "targetLowPrice": 20.0, "targetMeanPrice": 31.0, "targetMedianPrice": 26.25, "recommendationMean": 2.125, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 21101000704, "totalCashPerShare": 332.089, "ebitda": 7390000128, "totalDebt": 1029000000, "quickRatio": 5.236, "currentRatio": 5.248, "totalRevenue": 21525999616, "debtToEquity": 2.804, "revenuePerShare": 33.5366, "returnOnAssets": 0.109110005, "returnOnEquity": 0.22966999, "grossProfits": 20540999680, "freeCashflow": 6252375040, "operatingCashflow": 7770999808, "earningsGrowth": 4.634, "revenueGrowth": 0.353, "grossMargins": 0.95424, "ebitdaMargins": 0.34331, "operatingMargins": 0.35196, "financialCurrency": "DKK", "symbol": "GMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "epsTrailingTwelveMonths": 1.76, "epsForward": 1.4, "epsCurrentYear": 1.38229, "priceEpsCurrentYear": 13.499338, "fiftyDayAverageChange": -2.1557007, "fiftyDayAverageChangePercent": -0.10356128, "twoHundredDayAverageChange": -4.732525, "twoHundredDayAverageChangePercent": -0.20230928, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.1 - Buy", "cryptoTradeable": false, "marketState": "PRE", "regularMarketChangePercent": -4.6986723, "regularMarketPrice": 18.66, "shortName": "Genmab A/S", "longName": "Genmab A/S", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1243863000000, "preMarketChange": -0.11999893, "preMarketChangePercent": -0.64308107, "preMarketPrice": 18.54, "regularMarketChange": -0.9200001, "regularMarketDayRange": "18.622 - 19.1", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1512646, "fiftyTwoWeekLowChange": 0.038000107, "fiftyTwoWeekLowChangePercent": 0.002040603, "fiftyTwoWeekRange": "18.622 - 30.5", "fiftyTwoWeekHighChange": -11.84, "fiftyTwoWeekHighChangePercent": -0.38819674, "fiftyTwoWeekChangePercent": -36.31399, "earningsTimestamp": 1746716400, "earningsTimestampStart": 1746716400, "earningsTimestampEnd": 1746716400, "earningsCallTimestampStart": 1746720000, "earningsCallTimestampEnd": 1746720000, "isEarningsDateEstimate": false, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "preMarketTime": 1743595685, "regularMarketTime": 1743537600, "exchange": "NMS", "messageBoardId": "finmb_665704", "trailingPegRatio": 1.0271}